STOCK TITAN
  1. Home
  2. Sec-filings
  3. ORGO
  4. [Form 4] Organogenesis Holdings Inc. Insider Trading Activity

Executive equity awards at Organogenesis (ORGO) include RSUs, options and tax withholding

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Organogenesis Holdings Inc. vice president Robert Cavorsi reported multiple equity awards and a related tax share disposition. He received stock options for 53,452 shares at an exercise price of $0.00 and now holds 53,452 derivative securities. He was also granted 93,750 shares of Class A common stock and a further 16,290 shares, bringing his direct Class A holdings to 276,115 shares after all transactions.

The awards include restricted stock units that vest in equal annual installments over four years beginning February 15, 2026, and options that become exercisable on the same schedule. Some shares were issued from a 2025 performance share award tied to performance milestones. A total of 5,432 shares were withheld and disposed at $3.84 per share to cover tax obligations.

Positive

  • None.

Negative

  • None.

Insights

Filing shows routine equity awards and tax withholding, not open-market trading.

The transactions for Organogenesis Holdings Inc. involve grants of options, restricted stock units, and performance-based shares to executive Robert Cavorsi. All acquisition entries have a price of $0.00, consistent with compensation awards rather than market purchases.

The single dispose transaction is coded "F" and priced at $3.84 per share, indicating shares were withheld to satisfy tax or exercise obligations, not sold in the open market. Overall, this appears to be a standard annual equity compensation and vesting event, with no direct cash investment or discretionary selling.

Insider Cavorsi Robert
Role Vice President, Strategy
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 53,452 $0.00 --
Grant/Award Class A Common Stock 93,750 $0.00 --
Grant/Award Class A Common Stock 16,290 $0.00 --
Tax Withholding Class A Common Stock 5,432 $3.84 $21K
Holdings After Transaction: Stock Option (Right to Buy) — 53,452 shares (Direct); Class A Common Stock — 265,257 shares (Direct)
Footnotes (1)
  1. Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2026. Shares issued pursuant to the vesting and settlement of a performance share award granted in 2025 based on the achievement of certain performance milestones. The option becomes exercisable in equal annual installments over four years beginning February 15, 2026.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cavorsi Robert
(Last) (First) (Middle)
C/O ORGANOGENESIS HOLDINGS INC.
85 DAN ROAD
(Street)
CANTON MA 02021
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Organogenesis Holdings Inc. [ ORGO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Vice President, Strategy
3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 02/18/2026 A 93,750(1) A $0 265,257 D
Class A Common Stock 02/18/2026 A 16,290(2) A $0 281,547 D
Class A Common Stock 02/18/2026 F 5,432 D $3.84 276,115 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $3.84 02/18/2026 A 53,452 (3) 02/18/2036 Class A Common Stock 53,452 $0 53,452 D
Explanation of Responses:
1. Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2026.
2. Shares issued pursuant to the vesting and settlement of a performance share award granted in 2025 based on the achievement of certain performance milestones.
3. The option becomes exercisable in equal annual installments over four years beginning February 15, 2026.
/s/ William R. Kolb, Attorney-in-Fact 02/20/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What equity awards did ORGO executive Robert Cavorsi receive in this Form 4?

He received stock options for 53,452 shares and two Class A common stock awards totaling 110,040 shares. These include restricted stock units vesting over four years and shares from a 2025 performance award based on achieving specified performance milestones.

How many Organogenesis (ORGO) shares does Robert Cavorsi own after these transactions?

After the reported transactions, Robert Cavorsi directly holds 276,115 shares of Organogenesis Class A common stock. He also holds 53,452 derivative securities in the form of stock options, reflecting his updated post-award equity position at the company.

Were any ORGO shares sold by Robert Cavorsi in this Form 4 filing?

The filing shows a disposition of 5,432 shares at $3.84 per share coded "F," which denotes tax withholding. These shares were delivered to cover tax obligations related to equity awards, not sold as an open-market transaction.

How do the Organogenesis RSUs granted to Cavorsi vest over time?

The restricted stock units granted to Robert Cavorsi vest in equal annual installments over four years starting on February 15, 2026. Each vested unit entitles him to receive one share of Organogenesis Class A common stock upon settlement.

What are the vesting terms for Robert Cavorsi’s new ORGO stock options?

The 53,452 stock options granted to Robert Cavorsi become exercisable in equal annual installments over four years beginning on February 15, 2026. This schedule gradually increases his ability to purchase Organogenesis Class A common stock over time.

What is the nature of the performance share award mentioned in the ORGO Form 4?

Some shares were issued upon vesting and settlement of a performance share award granted in 2025. The number of shares delivered was based on the achievement of specified performance milestones outlined in that 2025 performance-based equity award.